PLoS ONE (Jan 2022)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

  • Manish A Shah,
  • Zev A Wainberg,
  • Daniel V T Catenacci,
  • Howard S Hochster,
  • James Ford,
  • Pamela Kunz,
  • Fa-Chyi Lee,
  • Howard Kallender,
  • Fabiola Cecchi,
  • Daniel C Rabe,
  • Harold Keer,
  • Anne-Marie Martin,
  • Yuan Liu,
  • Robert Gagnon,
  • Peter Bonate,
  • Li Liu,
  • Tona Gilmer,
  • Donald P Bottaro

DOI
https://doi.org/10.1371/journal.pone.0276211
Journal volume & issue
Vol. 17, no. 10
p. e0276211

Abstract

Read online

[This corrects the article DOI: 10.1371/journal.pone.0054014.].